| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 30 | 2023 | 186 | 7.610 |
Why?
|
| Tremor | 26 | 2022 | 93 | 7.030 |
Why?
|
| Parkinson Disease | 32 | 2025 | 591 | 6.700 |
Why?
|
| Fragile X Mental Retardation Protein | 32 | 2023 | 112 | 6.690 |
Why?
|
| Ataxia | 25 | 2022 | 75 | 5.990 |
Why?
|
| Parkinsonian Disorders | 11 | 2022 | 164 | 2.840 |
Why?
|
| Heterozygote | 11 | 2022 | 88 | 2.560 |
Why?
|
| Tinnitus | 6 | 2020 | 7 | 2.390 |
Why?
|
| Trinucleotide Repeat Expansion | 15 | 2023 | 42 | 2.350 |
Why?
|
| Humans | 104 | 2025 | 22823 | 1.990 |
Why?
|
| Neurology | 3 | 2022 | 35 | 1.850 |
Why?
|
| Female | 59 | 2025 | 12904 | 1.560 |
Why?
|
| Male | 59 | 2025 | 12400 | 1.490 |
Why?
|
| Cognition Disorders | 6 | 2021 | 691 | 1.430 |
Why?
|
| Aged | 45 | 2025 | 7412 | 1.410 |
Why?
|
| Middle Aged | 47 | 2025 | 7873 | 1.370 |
Why?
|
| Research Design | 6 | 2022 | 157 | 1.280 |
Why?
|
| Supranuclear Palsy, Progressive | 8 | 2020 | 21 | 1.120 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2020 | 119 | 1.120 |
Why?
|
| Postural Balance | 4 | 2020 | 103 | 1.080 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 124 | 1.030 |
Why?
|
| Phenotype | 10 | 2025 | 255 | 1.010 |
Why?
|
| Cerebellar Ataxia | 2 | 2021 | 4 | 0.950 |
Why?
|
| Trinucleotide Repeats | 2 | 2018 | 10 | 0.920 |
Why?
|
| Movement Disorders | 4 | 2016 | 57 | 0.910 |
Why?
|
| Executive Function | 2 | 2018 | 89 | 0.890 |
Why?
|
| Health Status Disparities | 1 | 2025 | 63 | 0.870 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 71 | 0.860 |
Why?
|
| Accidental Falls | 4 | 2020 | 104 | 0.830 |
Why?
|
| Biomedical Research | 2 | 2018 | 51 | 0.800 |
Why?
|
| Exercise Therapy | 3 | 2018 | 84 | 0.770 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 3717 | 0.720 |
Why?
|
| Mutation | 8 | 2023 | 321 | 0.700 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 155 | 0.690 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2021 | 4 | 0.690 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2015 | 4 | 0.680 |
Why?
|
| Cognition | 5 | 2022 | 947 | 0.670 |
Why?
|
| Patient Selection | 2 | 2018 | 166 | 0.660 |
Why?
|
| Adult | 22 | 2022 | 6896 | 0.660 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.640 |
Why?
|
| Nootropic Agents | 1 | 2020 | 11 | 0.640 |
Why?
|
| Attention | 1 | 2020 | 101 | 0.630 |
Why?
|
| Delphi Technique | 3 | 2022 | 24 | 0.630 |
Why?
|
| Auditory Perception | 2 | 2017 | 31 | 0.620 |
Why?
|
| United States | 6 | 2025 | 1762 | 0.610 |
Why?
|
| Walking | 3 | 2020 | 232 | 0.610 |
Why?
|
| Severity of Illness Index | 12 | 2020 | 795 | 0.610 |
Why?
|
| Quality of Life | 7 | 2025 | 559 | 0.590 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 190 | 0.590 |
Why?
|
| Hearing | 2 | 2021 | 14 | 0.580 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2023 | 258 | 0.570 |
Why?
|
| Case-Control Studies | 10 | 2021 | 481 | 0.570 |
Why?
|
| Dyskinesia, Drug-Induced | 3 | 2023 | 9 | 0.540 |
Why?
|
| Acoustics | 1 | 2017 | 12 | 0.540 |
Why?
|
| Memory Disorders | 2 | 2016 | 108 | 0.530 |
Why?
|
| Psychotherapy | 1 | 2017 | 38 | 0.530 |
Why?
|
| Deafness | 3 | 2022 | 12 | 0.520 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 111 | 0.520 |
Why?
|
| Cohort Studies | 8 | 2023 | 1412 | 0.510 |
Why?
|
| Treatment Outcome | 11 | 2022 | 2934 | 0.490 |
Why?
|
| Genetic Testing | 6 | 2021 | 46 | 0.490 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 759 | 0.490 |
Why?
|
| Cerebral Hemorrhage | 4 | 2021 | 103 | 0.490 |
Why?
|
| Antipsychotic Agents | 2 | 2023 | 50 | 0.480 |
Why?
|
| DNA Methylation | 1 | 2016 | 129 | 0.470 |
Why?
|
| Water Pollution, Chemical | 1 | 2015 | 1 | 0.460 |
Why?
|
| Pesticide Residues | 1 | 2015 | 2 | 0.460 |
Why?
|
| Herbicides | 1 | 2015 | 2 | 0.460 |
Why?
|
| Groundwater | 1 | 2015 | 2 | 0.460 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 7 | 0.460 |
Why?
|
| Neuropsychological Tests | 8 | 2022 | 865 | 0.450 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 1019 | 0.420 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 47 | 0.400 |
Why?
|
| Prevalence | 4 | 2020 | 375 | 0.380 |
Why?
|
| Activities of Daily Living | 4 | 2017 | 356 | 0.370 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 95 | 0.370 |
Why?
|
| Speech Disorders | 2 | 2020 | 10 | 0.370 |
Why?
|
| Deep Brain Stimulation | 2 | 2022 | 36 | 0.360 |
Why?
|
| Alleles | 3 | 2020 | 164 | 0.360 |
Why?
|
| Cognitive Dysfunction | 2 | 2020 | 737 | 0.350 |
Why?
|
| Brain Ischemia | 2 | 2021 | 61 | 0.350 |
Why?
|
| Communication Disorders | 1 | 2011 | 3 | 0.350 |
Why?
|
| Consensus | 3 | 2022 | 81 | 0.340 |
Why?
|
| Gait | 4 | 2020 | 381 | 0.330 |
Why?
|
| Chromosomes, Human, X | 2 | 2009 | 7 | 0.330 |
Why?
|
| Cochlear Implantation | 2 | 2021 | 18 | 0.330 |
Why?
|
| Retrospective Studies | 8 | 2018 | 2976 | 0.330 |
Why?
|
| Walking Speed | 2 | 2022 | 34 | 0.320 |
Why?
|
| Dopamine | 1 | 2010 | 77 | 0.320 |
Why?
|
| Shoulder Pain | 1 | 2010 | 48 | 0.320 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2009 | 1 | 0.320 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 1 | 0.320 |
Why?
|
| Speech Perception | 2 | 2021 | 47 | 0.320 |
Why?
|
| Risk Factors | 8 | 2021 | 1966 | 0.310 |
Why?
|
| Levodopa | 3 | 2023 | 34 | 0.310 |
Why?
|
| Prospective Studies | 6 | 2025 | 1487 | 0.310 |
Why?
|
| Motor Activity | 3 | 2021 | 267 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2020 | 370 | 0.300 |
Why?
|
| Child | 6 | 2022 | 1153 | 0.300 |
Why?
|
| DNA Repeat Expansion | 2 | 2006 | 6 | 0.300 |
Why?
|
| Incidence | 4 | 2020 | 624 | 0.300 |
Why?
|
| Quinolones | 1 | 2009 | 11 | 0.300 |
Why?
|
| Sex Factors | 4 | 2022 | 384 | 0.290 |
Why?
|
| Young Adult | 5 | 2015 | 1647 | 0.280 |
Why?
|
| Piperazines | 1 | 2009 | 82 | 0.280 |
Why?
|
| Observational Studies as Topic | 2 | 2025 | 15 | 0.270 |
Why?
|
| Students, Health Occupations | 1 | 2007 | 3 | 0.270 |
Why?
|
| Science | 1 | 2007 | 4 | 0.270 |
Why?
|
| Celiac Disease | 1 | 2007 | 7 | 0.260 |
Why?
|
| Dystonia | 1 | 2007 | 10 | 0.260 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 24 | 0.260 |
Why?
|
| RNA, Messenger | 4 | 2023 | 271 | 0.260 |
Why?
|
| Teaching | 1 | 2007 | 46 | 0.260 |
Why?
|
| Age of Onset | 4 | 2016 | 71 | 0.260 |
Why?
|
| Fetal Distress | 1 | 2006 | 1 | 0.250 |
Why?
|
| Pregnancy in Diabetics | 1 | 2006 | 4 | 0.250 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 7 | 0.250 |
Why?
|
| Brain | 5 | 2022 | 1202 | 0.250 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 12 | 0.250 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 17 | 0.250 |
Why?
|
| Colorado | 3 | 2015 | 5 | 0.250 |
Why?
|
| Seizures | 1 | 2006 | 62 | 0.240 |
Why?
|
| Disability Evaluation | 5 | 2016 | 218 | 0.240 |
Why?
|
| Feces | 2 | 2023 | 80 | 0.240 |
Why?
|
| Water Wells | 2 | 2016 | 2 | 0.240 |
Why?
|
| Adolescent | 5 | 2015 | 1874 | 0.240 |
Why?
|
| Gait Ataxia | 1 | 2005 | 5 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2016 | 17 | 0.230 |
Why?
|
| Time Factors | 5 | 2020 | 1258 | 0.230 |
Why?
|
| Glucosylceramidase | 2 | 2022 | 13 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 25 | 0.230 |
Why?
|
| Prion Diseases | 1 | 2005 | 2 | 0.230 |
Why?
|
| Prions | 1 | 2005 | 6 | 0.230 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 1319 | 0.220 |
Why?
|
| Eye Diseases | 1 | 2004 | 8 | 0.220 |
Why?
|
| Intellectual Disability | 1 | 2005 | 43 | 0.220 |
Why?
|
| England | 2 | 2015 | 14 | 0.220 |
Why?
|
| Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.220 |
Why?
|
| Eye Movements | 2 | 2021 | 10 | 0.210 |
Why?
|
| Chorea | 1 | 2004 | 5 | 0.210 |
Why?
|
| Antiparkinson Agents | 1 | 2023 | 41 | 0.200 |
Why?
|
| Mental Disorders | 1 | 2005 | 134 | 0.200 |
Why?
|
| Corpus Callosum | 1 | 2003 | 10 | 0.200 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1047 | 0.200 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2021 | 88 | 0.200 |
Why?
|
| Basal Ganglia Diseases | 1 | 2023 | 3 | 0.200 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 99 | 0.200 |
Why?
|
| Caregivers | 2 | 2022 | 185 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 15 | 0.200 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 26 | 0.200 |
Why?
|
| Prebiotics | 1 | 2023 | 18 | 0.200 |
Why?
|
| Career Mobility | 1 | 2022 | 13 | 0.190 |
Why?
|
| ran GTP-Binding Protein | 1 | 2022 | 3 | 0.190 |
Why?
|
| Biomechanical Phenomena | 4 | 2020 | 537 | 0.190 |
Why?
|
| Health Facilities | 1 | 2022 | 26 | 0.190 |
Why?
|
| Homebound Persons | 1 | 2022 | 6 | 0.190 |
Why?
|
| Cerebral Infarction | 1 | 2003 | 109 | 0.190 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 13 | 0.190 |
Why?
|
| Neurosecretory Systems | 1 | 2022 | 5 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 9 | 0.190 |
Why?
|
| Mentoring | 1 | 2022 | 24 | 0.190 |
Why?
|
| Weather | 2 | 2019 | 13 | 0.180 |
Why?
|
| Multiple System Atrophy | 1 | 2022 | 26 | 0.180 |
Why?
|
| Subthalamic Nucleus | 1 | 2022 | 19 | 0.180 |
Why?
|
| Dopamine Agents | 1 | 2021 | 11 | 0.180 |
Why?
|
| Food | 1 | 2021 | 30 | 0.180 |
Why?
|
| Exercise | 2 | 2017 | 392 | 0.180 |
Why?
|
| Comprehension | 2 | 2016 | 25 | 0.180 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2021 | 8 | 0.180 |
Why?
|
| Chicago | 2 | 2021 | 811 | 0.170 |
Why?
|
| Ovary | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hypertension | 2 | 2019 | 163 | 0.170 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 11 | 0.170 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2019 | 94 | 0.170 |
Why?
|
| Dementia | 1 | 2005 | 388 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2019 | 117 | 0.170 |
Why?
|
| Animals | 5 | 2022 | 3255 | 0.170 |
Why?
|
| Telemedicine | 1 | 2022 | 84 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2020 | 27 | 0.170 |
Why?
|
| Martial Arts | 1 | 2020 | 4 | 0.170 |
Why?
|
| Vision Disorders | 1 | 2020 | 19 | 0.170 |
Why?
|
| Menopause | 1 | 2021 | 99 | 0.160 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2020 | 99 | 0.160 |
Why?
|
| Hearing Aids | 1 | 2020 | 2 | 0.160 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 16 | 0.160 |
Why?
|
| Chemokine CCL5 | 1 | 2019 | 9 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2019 | 23 | 0.150 |
Why?
|
| Electroencephalography | 2 | 2013 | 70 | 0.150 |
Why?
|
| Independent Living | 1 | 2021 | 225 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 96 | 0.150 |
Why?
|
| Genotype | 3 | 2016 | 246 | 0.150 |
Why?
|
| Research Subjects | 1 | 2018 | 9 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2018 | 11 | 0.150 |
Why?
|
| Sample Size | 1 | 2018 | 17 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 438 | 0.150 |
Why?
|
| Dopaminergic Neurons | 1 | 2019 | 39 | 0.150 |
Why?
|
| Substantia Nigra | 1 | 2019 | 101 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2022 | 307 | 0.140 |
Why?
|
| Pedigree | 3 | 2008 | 50 | 0.140 |
Why?
|
| High-Intensity Interval Training | 1 | 2018 | 1 | 0.140 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 12 | 0.140 |
Why?
|
| Estrogens | 1 | 2018 | 26 | 0.140 |
Why?
|
| Ibuprofen | 1 | 2017 | 9 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 69 | 0.140 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 8 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2017 | 22 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2010 | 1412 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 146 | 0.130 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2017 | 3 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 86 | 0.130 |
Why?
|
| Exercise Test | 1 | 2018 | 112 | 0.130 |
Why?
|
| Mosaicism | 1 | 2016 | 7 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 14 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 30 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 61 | 0.120 |
Why?
|
| Uric Acid | 1 | 2016 | 7 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 364 | 0.120 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 564 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 2016 | 21 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 14 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 50 | 0.120 |
Why?
|
| Age Factors | 3 | 2021 | 633 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 78 | 0.120 |
Why?
|
| Audiometry | 1 | 2015 | 6 | 0.120 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 2015 | 1 | 0.120 |
Why?
|
| Water Quality | 1 | 2015 | 1 | 0.120 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 8 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 64 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2005 | 49 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 23 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 216 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 160 | 0.110 |
Why?
|
| Dopamine Agonists | 2 | 2021 | 15 | 0.110 |
Why?
|
| Medicare | 1 | 2015 | 106 | 0.110 |
Why?
|
| Disease Progression | 4 | 2016 | 521 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 858 | 0.100 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 309 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 17 | 0.100 |
Why?
|
| Auditory Pathways | 1 | 2013 | 1 | 0.100 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2013 | 7 | 0.100 |
Why?
|
| Psychoacoustics | 1 | 2013 | 7 | 0.100 |
Why?
|
| Registries | 2 | 2022 | 173 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 8 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 51 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 38 | 0.100 |
Why?
|
| Equipment Design | 1 | 2013 | 120 | 0.100 |
Why?
|
| House Calls | 2 | 2022 | 15 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2013 | 373 | 0.090 |
Why?
|
| Neurologic Examination | 3 | 2008 | 80 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 152 | 0.090 |
Why?
|
| Language Disorders | 1 | 2011 | 6 | 0.090 |
Why?
|
| Social Behavior Disorders | 1 | 2011 | 5 | 0.090 |
Why?
|
| Memantine | 1 | 2010 | 7 | 0.080 |
Why?
|
| Cyclohexanols | 1 | 2010 | 18 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2011 | 217 | 0.080 |
Why?
|
| Cocaine | 1 | 2010 | 31 | 0.080 |
Why?
|
| Point Mutation | 2 | 2008 | 25 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2010 | 63 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 75 | 0.080 |
Why?
|
| Family Health | 2 | 2007 | 29 | 0.080 |
Why?
|
| Herpes Zoster | 1 | 2009 | 4 | 0.080 |
Why?
|
| Atmospheric Pressure | 2 | 2019 | 8 | 0.080 |
Why?
|
| Brown-Sequard Syndrome | 1 | 2009 | 4 | 0.080 |
Why?
|
| Atrophy | 2 | 2008 | 68 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 477 | 0.070 |
Why?
|
| Aripiprazole | 1 | 2009 | 7 | 0.070 |
Why?
|
| Palate, Soft | 1 | 2008 | 1 | 0.070 |
Why?
|
| Alexander Disease | 1 | 2008 | 1 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 10 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2009 | 563 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 55 | 0.070 |
Why?
|
| Glutens | 1 | 2007 | 1 | 0.070 |
Why?
|
| Jejunum | 1 | 2007 | 10 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 22 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2007 | 12 | 0.070 |
Why?
|
| Education | 1 | 2007 | 31 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 23 | 0.070 |
Why?
|
| North America | 2 | 2018 | 32 | 0.070 |
Why?
|
| Universities | 1 | 2007 | 35 | 0.070 |
Why?
|
| Carbidopa | 1 | 2006 | 4 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 27 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 12 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 45 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 26 | 0.060 |
Why?
|
| Biopsy | 1 | 2007 | 186 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 77 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2006 | 102 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 157 | 0.060 |
Why?
|
| Pregnancy | 1 | 2006 | 324 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 66 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 34 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2006 | 163 | 0.060 |
Why?
|
| Health Surveys | 1 | 2005 | 76 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2006 | 534 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 517 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 19 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2023 | 24 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2023 | 27 | 0.050 |
Why?
|
| Agraphia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Dyslexia, Acquired | 1 | 2003 | 1 | 0.050 |
Why?
|
| Auditory Perceptual Disorders | 1 | 2003 | 2 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 126 | 0.050 |
Why?
|
| Metagenome | 1 | 2023 | 15 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 168 | 0.050 |
Why?
|
| Neurons | 1 | 2005 | 273 | 0.050 |
Why?
|
| Mentors | 1 | 2022 | 34 | 0.050 |
Why?
|
| Guanine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 43 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 12 | 0.050 |
Why?
|
| Stroke | 1 | 2005 | 241 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 36 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 61 | 0.050 |
Why?
|
| Peptides | 1 | 2022 | 89 | 0.050 |
Why?
|
| Physical Therapy Modalities | 2 | 2012 | 58 | 0.040 |
Why?
|
| Genetic Background | 1 | 2021 | 2 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2021 | 9 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 17 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 17 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 23 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 64 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 159 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 572 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 226 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 235 | 0.040 |
Why?
|
| Noise | 1 | 2020 | 24 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 210 | 0.040 |
Why?
|
| Cochlear Implants | 1 | 2020 | 25 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 2019 | 34 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 546 | 0.040 |
Why?
|
| Temperature | 1 | 2018 | 57 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 714 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 285 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 363 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 426 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 350 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 194 | 0.030 |
Why?
|
| Accelerometry | 1 | 2017 | 78 | 0.030 |
Why?
|
| Posture | 1 | 2016 | 56 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 20 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2016 | 17 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 100 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1228 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 28 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 86 | 0.020 |
Why?
|
| Movement | 1 | 2013 | 103 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 255 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 94 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 200 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 103 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 123 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 193 | 0.020 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2010 | 17 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 162 | 0.020 |
Why?
|
| Geniculate Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
| Superior Cervical Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 4 | 0.020 |
Why?
|
| Intelligence | 1 | 2008 | 14 | 0.020 |
Why?
|
| Mental Processes | 1 | 2008 | 15 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 25 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 38 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 79 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 22 | 0.020 |
Why?
|
| Mass Screening | 1 | 2007 | 159 | 0.010 |
Why?
|
| California | 1 | 2004 | 35 | 0.010 |
Why?
|